Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VisionHealth

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

- PMLiVE

Boehringer beefs up biologics capacity with €230m investment

New facility to focus on analytical and process development and manufacturing of biologics for trials.

AstraZeneca AZ

PMCPA takes AZ to task over asthma drug press release

Concluded that the data in the release had not been “placed in context”

EphMRA Annual Conference 2018

Visit us on stand number 20

Research Partnership

Boehringer Ingelheim headquarters

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

- PMLiVE

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Offers €15m upfront for the anti-SIRP-alpha antibody and €15m when it reaches phase I testing

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Boehringer Ingelheim headquarters

Boehringer adds to pipeline again with €628m Autifony CNS deal

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

AstraZeneca AZ

AZ prices severe asthma drug Fasenra below competition

The discounted drug will cost $38,000 in the first year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links